Patents Assigned to Enzon Pharmaceuticals
  • Publication number: 20140031409
    Abstract: The invention provides the combination use of antisense oligomers targeting androgen receptor mRNA and androgen receptor binding inhibitors that reduce androgen receptor activity for the treatment of androgen receptor related medical disorders, such as cancers, particularly prostate cancers and breast cancers.
    Type: Application
    Filed: April 30, 2013
    Publication date: January 30, 2014
    Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals
    Inventors: Jesper Worm, Yixian Zhang
  • Publication number: 20120088907
    Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
    Type: Application
    Filed: July 14, 2011
    Publication date: April 12, 2012
    Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals
    Inventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
  • Publication number: 20100292311
    Abstract: Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
    Type: Application
    Filed: April 22, 2010
    Publication date: November 18, 2010
    Applicants: Enzon Pharmaceuticals, Santaris Pharma A/S
    Inventors: Bo Hansen, Charlotte Albaek Thrue, Majken Westergaard, Kamille Dumong Petersen, Margit Wissenbach
  • Patent number: 7584675
    Abstract: Connector which provide conduits between a sealed environment and an exterior of the environment includes a housing, a plurality of internal conduits extending from a first side of the housing, each adapted to communicate with a respective sampling device situated in the sealed environment, and a single external conduit extending from a second side of the housing opposite the first side and adapted to communicate with a measurement device exterior of the sealed environment. The housing is constructed to enable each internal conduits to alternatingly align with the external conduit such that each sampling device is able to communicate with the measurement device. By providing a connector which is able to provide a flow passage between multiple sampling devices and a single measurement device, at different times, it is not necessary to enter the sealed environment in order to configure a single sampling device in communication with the measurement device.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: September 8, 2009
    Assignee: Enzon Pharmaceuticals
    Inventor: Roy L. Evans